Prognosis and Risks for Probable Chronic Lung Allograft Dysfunction: A Prospective Multicenter Study.

acute rejection chronic lung allograft dysfunction lung transplantation

Journal

American journal of respiratory and critical care medicine
ISSN: 1535-4970
Titre abrégé: Am J Respir Crit Care Med
Pays: United States
ID NLM: 9421642

Informations de publication

Date de publication:
29 Oct 2024
Historique:
medline: 29 10 2024
pubmed: 29 10 2024
entrez: 29 10 2024
Statut: aheadofprint

Résumé

Chronic lung allograft dysfunction (CLAD) hinders lung transplant success. A 2019 consensus refined CLAD diagnosis, introducing probable or definite CLAD based on persistence of lung function decline. Outcomes and risks for probable CLAD remain uncertain. Determine the prognosis and clinical risks for probable CLAD in a prospective multicenter cohort. Clinical Trials in Organ Transplantation-20 included 745 CLAD-eligible adult lung recipients at 5 centers and applied rigorous methods to prospectively adjudicate probable CLAD. The impact of probable CLAD on graft loss was determined using a Cox model that considered CLAD as a time-dependent covariate. Regularized Cox modeling with LASSO penalty was used to evaluate donor or recipient characteristics and the occurrence and timing of posttransplant events as probable CLAD risks. Similar analyses were performed for definite CLAD. Probable CLAD occurred in 29.7% of patients at 3 years posttransplant and conferred a marked increase in risk for graft loss (unadjusted HR 4.38, p<0.001). Most patients (80%) with probable CLAD progressed to definite CLAD. Cytomegalovirus infection and specifically late presence (>90 days posttransplant) of donor-specific alloantibodies, acute rejection, acute lung injury, or organizing pneumonia contributed the greatest independent information about probable CLAD risk. Definite CLAD risks were similar. Probable CLAD identifies patients at high risk for graft loss, supporting prospective identification of this condition for early initiation of CLAD-directed interventions. More effective strategies to prevent posttransplant cytomegalovirus, inhibit allospecific immunity, and reduce tissue injury are needed to reduce probable CLAD and improve lung recipient survival.

Identifiants

pubmed: 39470452
doi: 10.1164/rccm.202403-0568OC
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Jamie L Todd (JL)

Duke University School of Medicine, Durham, North Carolina, United States.
Duke Clinical Research Institute, Durham, North Carolina, United States; jamie.todd@duke.edu.

S Sam Weigt (SS)

UCLA, Medicine, Los Angeles, California, United States.

Megan L Neely (ML)

Duke Clinical Research Institute, Durham, North Carolina, United States.
Duke University, Department of Biostatistics and Bioinformatics, Durham, North Carolina, United States.

Maria V Grau-Sepulveda (MV)

Duke Clinical Research Institute, Durham, North Carolina, United States.

Kristen Mason (K)

Rho, Durham, United States.

Michelle L Sever (ML)

Rho, Durham, United States.

Karen Kesler (K)

Rho, Durham, North Carolina, United States.

Jerry Kirchner (J)

Duke Clinical Research Institute, Durham, North Carolina, United States.

Courtney W Frankel (CW)

Duke University School of Medicine, Durham, North Carolina, United States.

Tereza Martinu (T)

University of Toronto, Medicine, Toronto, Ontario, Canada.

Michael Y Shino (MY)

UCLA, Pulmonary and Critical Care Medicine, Westwood, CA, California, United States.

Annette M Jackson (AM)

Duke University School of Medicine, Durham, North Carolina, United States.

Elizabeth N Pavlisko (EN)

Duke University, Pathology, Durham, North Carolina, United States.

Nikki Williams (N)

National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States.

Mark A Robien (MA)

National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States.

Lianne G Singer (LG)

University of Toronto, Medicine, Toronto, Ontario, Canada.
University Health Network, Medicine.

Marie Budev (M)

The Cleveland Clinic , Respiratory Institute , Cleveland , Ohio, United States.

Wayne Tsuang (W)

Duke, Durham, United States.

Pali D Shah (PD)

Johns Hopkins University School of Medicine, Pulmonary/Respiratory, Baltimore, Maryland, United States.

John M Reynolds (JM)

Duke University School of Medicine, Durham, North Carolina, United States.

Laurie D Snyder (LD)

Duke University, Medicine, Durham, North Carolina, United States.

John A Belperio (JA)

UCLA, LA, California, United States.

Scott M Palmer (SM)

Duke University, Medicine - Pulmonary, Allergy, and Critical Care, Durham, North Carolina, United States.

Classifications MeSH